Insight Molecular (IMDX) Fundamental Analysis: Revenue, Earnings & Valuation

2.86 / 10

Underperform

Fundamental evaluation is subpar (2.9/10). While revenue and profit metrics relative to market value show promise, concerns arise from the fixed assets turnover ratio and the net profit to total profit percentage. The PB-ROE factor of 1.1345 places the stock in a higher-risk quartile, historically yielding only 3.56% monthly returns with a 53.2% win rate, indicating limited upside potential.

Analysis Checks(6/10)

Revenue-MV

Value-4.28

Score2/3

Weight25.67%

1M Return11.69%

Inventory turnover ratio

Value2.53

Score2/3

Weight-4.27%

1M Return-2.63%

Gross profit margin (%)

Value61.80

Score2/3

Weight2.78%

1M Return1.47%

Profit-MV

Value0.46

Score2/3

Weight16.84%

1M Return7.79%

PB-ROE

Value1.13

Score0/3

Weight7.69%

1M Return3.56%

Current assets turnover ratio

Value0.18

Score1/3

Weight-0.85%

1M Return-0.48%

Fixed assets turnover ratio

Value0.46

Score1/3

Weight-2.67%

1M Return-1.64%

Asset-MV

Value-0.50

Score2/3

Weight38.43%

1M Return15.13%

Cash-MV

Value-0.07

Score2/3

Weight16.87%

1M Return7.73%

Net profit / Total profit (%)

Value100.00

Score0/3

Weight-0.50%

1M Return-0.30%

Is IMDX fundamentally strong?

IMDX scores 2.86/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -1380.69% net margin, -3.31 P/E ratio, -22.82 P/B ratio, and 27.54% earnings growth, these metrics solidify its Underperform investment rating.